Rubicon Genomics Overview
- Year Founded
-
2000
- Status
-
Acquired/Merged
- Employees
-
32
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$75M
Rubicon Genomics General Information
Description
Provider of amplification technologies designed for detecting the pattern of DNA methylation in cancer cells. The company develops a test to non-invasively diagnose cancer and other diseases to amplify the exceedingly small amounts of abnormally methylated DNA that are released by diseased tissue into serum and urine, enabling physicians to access non-invasive tests for cancer.
Contact Information
Website
www.rubicongenomics.comCorporate Office
- 4743 Venture Drive
- Ann Arbor, MI 48108
- United States
Corporate Office
- 4743 Venture Drive
- Ann Arbor, MI 48108
- United States
Rubicon Genomics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Merger/Acquisition | 17-Jan-2017 | $75M | Completed | Generating Revenue | ||
| 5. Accelerator/Incubator | Completed | Generating Revenue | ||||
| 4. Debt - General | 15-Jul-2015 | Completed | Generating Revenue | |||
| 3. Later Stage VC (Series B1) | 13-Nov-2007 | Completed | Generating Revenue | |||
| 2. Early Stage VC | 03-Jun-2005 | $2.63M | $4.12M | Completed | Startup | |
| 1. Early Stage VC (Series B) | 01-Feb-2003 | $1.49M | $1.49M | Completed | Startup |
Rubicon Genomics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B1 | ||||||||
| Series B | ||||||||
| Series A | 875,000 | $0.010000 | $2 | $2 | 1x | $2 | 4.18% |
Rubicon Genomics Comparisons
Industry
Financing
Details
Rubicon Genomics Competitors (19)
One of Rubicon Genomics’s 19 competitors is Treventis, a Venture Capital-Backed company based in Toronto, Canada.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Treventis | Venture Capital-Backed | Toronto, Canada | ||||
| Personal Genome Diagnostics | Formerly VC-backed | Baltimore, MD | ||||
| Palvella Therapeutics | Formerly VC-backed | Wayne, PA | ||||
| Sphere Fluidics | Formerly VC-backed | Cambridge, United Kingdom | ||||
| New England Biolabs | Corporation | Ipswich, MA |
Rubicon Genomics Patents
Rubicon Genomics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2016160965-A1 | Methods and compositions for repair of dna ends by multiple enzymatic activities | Inactive | 30-Mar-2015 | ||
| WO-2016145039-A1 | Enhanced fragmentation and repair of nucleic acids | Inactive | 10-Mar-2015 | ||
| WO-2015074017-A1 | Degradable adaptors for background reduction | Inactive | 18-Nov-2013 | ||
| WO-2014071361-A1 | Barcoding nucleic acids | Inactive | 05-Nov-2012 | ||
| EP-1924704-A1 | Compositions and methods for processing and amplification of dna, including using multiple enzymes in a single reaction | Active | 02-Aug-2005 | C12P19/34 |
Rubicon Genomics Signals
Rubicon Genomics Former Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Arch Development Partners | Venture Capital | Minority | ||
| BroadOak Capital Partners | Growth/Expansion | Minority | ||
| Duchossois Technology Partners | Corporate Venture Capital | Minority | ||
| Innovation Partnerships | Venture Capital | Minority | ||
| Michigan Economic Development | Government |
Rubicon Genomics FAQs
-
When was Rubicon Genomics founded?
Rubicon Genomics was founded in 2000.
-
Where is Rubicon Genomics headquartered?
Rubicon Genomics is headquartered in Ann Arbor, MI.
-
What is the size of Rubicon Genomics?
Rubicon Genomics has 32 total employees.
-
What industry is Rubicon Genomics in?
Rubicon Genomics’s primary industry is Discovery Tools (Healthcare).
-
Is Rubicon Genomics a private or public company?
Rubicon Genomics is a Private company.
-
What is the current valuation of Rubicon Genomics?
The current valuation of Rubicon Genomics is .
-
What is Rubicon Genomics’s current revenue?
The current revenue for Rubicon Genomics is .
-
How much funding has Rubicon Genomics raised over time?
Rubicon Genomics has raised $12M.
-
Who are Rubicon Genomics’s investors?
Arch Development Partners, BroadOak Capital Partners, Duchossois Technology Partners, Innovation Partnerships, and Michigan Economic Development are 5 of 8 investors who have invested in Rubicon Genomics.
-
Who are Rubicon Genomics’s competitors?
Treventis, Personal Genome Diagnostics, Palvella Therapeutics, Sphere Fluidics, and New England Biolabs are some of the 19 competitors of Rubicon Genomics.
-
When was Rubicon Genomics acquired?
Rubicon Genomics was acquired on 17-Jan-2017.
-
Who acquired Rubicon Genomics?
Rubicon Genomics was acquired by Takara Bio USA.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process